Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03896620 · ClinicalTrials.gov registry record
Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma
A clinical trial of Sarcoma, sponsored by Medical College of Wisconsin.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT03896620: Recruiting study of Sarcoma, sponsored by Medical College of Wisconsin.
NCT03896620 is a study of Sarcoma that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 50 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03896620, a study of Sarcoma, is actively recruiting participants, sponsored by Medical College of Wisconsin.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
A tissue biopsy is currently the only clinical test or procedure that is able to confirm the initial diagnosis of soft tissue or metastatic sarcoma and evaluate its progress during treatment. However, tissue biopsy collection can be challenging (depending on the location of the tumor), and this procedure poses physical risks to the patient. A tissue biopsy also needs to be recollected at various time points in order to assess if the patient is responding to treatment. In this project, the investigator would like to collect blood samples in addition to the sample of the tumor that will be collected before treatment is started. The investigator would like to analyze both blood and tumor, in hopes of identifying new biomarkers of sarcoma that can help the study doctors better diagnose sarcoma for patients in the future without needing to collect a piece of their tumor. A biomarker is something found in the blood, other body fluids, or tissues that can be used to measure the progress of disease, how a treatment is working, or its likelihood of being successful. In this project, the investigator would like to compare ctDNA from blood to the DNA in the tumor. ctDNA, or circulating tumor DNA, is DNA originating from the tumor that is present in the blood. It can be assessed by taking an additional sample of blood when it will be collected for normal laboratory tests. These biomarkers may also help the study doctors detect how a patient is responding to their treatment or help predict their response to future treatment.
Primary Outcome
Blood samples will be collected. ctDNA is measured in percentage: variant allele fraction percentage.
Conditions Studied
Interventions
- DRUG Chemotherapy
- DEVICE Preoperative RT
- DEVICE Postoperative RT
- OTHER Surgery
Study Locations (1)
Wisconsin
- Froedtert Hospital & the Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2019-06-18 |
| Est. Completion | 2026-06-01 |
What NCT03896620 shows while recruiting
NCT03896620 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 4 interventions - of which Chemotherapy is the first listed.
NCT03896620 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03896620 about?
NCT03896620 is a clinical study titled "Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma". A tissue biopsy is currently the only clinical test or procedure that is able to confirm the initial diagnosis of soft tissue or metastatic sarcoma and evaluate its progress during treatment. However, tissue biopsy collection can be challenging (depending on the location of the tumor), and this proc...
What is the current status of trial NCT03896620?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2019-06-18. Estimated completion is 2026-06-01.
What conditions does trial NCT03896620 study?
This clinical trial studies the following conditions: Sarcoma.
What interventions are being tested in trial NCT03896620?
The interventions under investigation include: Chemotherapy (DRUG), Preoperative RT (DEVICE), Postoperative RT (DEVICE), Surgery (OTHER).
Who is sponsoring clinical trial NCT03896620?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03896620 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03896620's enrollment target sits among peer trials
50 67th of 122 higher than 55 of 122 other Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
RECRUITING · NA
-
LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients
RECRUITING
-
Palbociclib and Pembrolizumab in Sarcoma
RECRUITING · Phase 1
-
Abductor Reattachment Methods in Proximal Femur Replacements: What is the Best Method?
RECRUITING
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Enhanced Recovery After Surgery in Extremity Sarcoma
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy